Shares of Heron Therapeutics Inc. (NASDAQ:HRTX) have been assigned a consensus rating of “Buy” from the nine research firms that are currently covering the company. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $41.50.

A number of research firms have recently weighed in on HRTX. Leerink Swann reaffirmed an “outperform” rating and set a $33.00 price target on shares of Heron Therapeutics in a research note on Thursday, August 18th. Brean Capital reaffirmed a “buy” rating and set a $55.00 price target on shares of Heron Therapeutics in a research note on Saturday, August 13th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $38.00 price target on shares of Heron Therapeutics in a research note on Tuesday, August 9th. Zacks Investment Research downgraded Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 3rd. Finally, JMP Securities reissued a “buy” rating on shares of Heron Therapeutics in a research note on Friday, September 9th.

Heron Therapeutics (NASDAQ:HRTX) opened at 15.70 on Monday. The stock’s 50 day moving average price is $18.23 and its 200 day moving average price is $18.89. Heron Therapeutics has a 1-year low of $15.13 and a 1-year high of $31.32.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.96) by $0.21. Equities analysts expect that Heron Therapeutics will post ($4.39) EPS for the current year.

In other Heron Therapeutics news, insider Robert Rosen sold 100,000 shares of Heron Therapeutics stock in a transaction that occurred on Wednesday, August 10th. The stock was sold at an average price of $23.30, for a total value of $2,330,000.00. Following the transaction, the insider now directly owns 102,640 shares of the company’s stock, valued at approximately $2,391,512. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 20.31% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Brown Advisory Inc. increased its position in shares of Heron Therapeutics by 3.9% in the second quarter. Brown Advisory Inc. now owns 307,827 shares of the biotechnology company’s stock valued at $5,557,000 after buying an additional 11,471 shares in the last quarter. Nationwide Fund Advisors increased its position in shares of Heron Therapeutics by 10.2% in the second quarter. Nationwide Fund Advisors now owns 20,730 shares of the biotechnology company’s stock valued at $374,000 after buying an additional 1,920 shares in the last quarter. State Board of Administration of Florida Retirement System increased its position in shares of Heron Therapeutics by 8.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 16,739 shares of the biotechnology company’s stock valued at $302,000 after buying an additional 1,283 shares in the last quarter. DIAM Co. Ltd. increased its position in shares of Heron Therapeutics by 7.7% in the second quarter. DIAM Co. Ltd. now owns 300,337 shares of the biotechnology company’s stock valued at $5,406,000 after buying an additional 21,473 shares in the last quarter. Finally, Emerald Acquisition Ltd. acquired a new position in shares of Heron Therapeutics during the second quarter valued at approximately $451,000.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

5 Day Chart for NASDAQ:HRTX

Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.